InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+6.6%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Castella Maelys, Membre du Conseil. Officer active across 1 company, notably UCB. Aggregated, 13 disclosures have been logged. History available since 30 September 2025. The latest transaction was disclosed on 6 November 2025 (Purchase). Regulator: FSMA. All data is free.
Declarations13 total
200 shares@ €216.0017.5% of flowShareEuronext BrusselsFSMA:ucb-94
Ideal exit: 3 Aug 2026 (T+270)
120 shares@ €221.0010.7% of flowShareEuronext BrusselsFSMA:ucb-186
Ideal exit: 28 Jul 2026 (T+270)
60 shares@ €236.505.7% of flowShareEuronext BrusselsFSMA:ucb-193
Ideal exit: 24 Jul 2026 (T+270)
100 shares@ €227.009.2% of flowShareEuronext BrusselsFSMA:ucb-14
Ideal exit: 25 Jul 2026 (T+270)
50 shares@ €233.004.7% of flowShareEuronext BrusselsFSMA:ucb-195
Ideal exit: 25 Jul 2026 (T+270)
50 shares@ €245.005.0% of flowShareEuronext BrusselsFSMA:ucb-13
Ideal exit: 21 Jul 2026 (T+270)
150 shares@ €224.0013.6% of flowShareEuronext BrusselsFSMA:ucb-64
Ideal exit: 28 Jul 2026 (T+270)
50 shares@ €245.505.0% of flowShareEuronext BrusselsFSMA:ucb-36
Ideal exit: 20 Jul 2026 (T+270)
50 shares@ €234.004.7% of flowShareEuronext BrusselsFSMA:ucb-65
Ideal exit: 24 Jul 2026 (T+270)
70 shares@ €250.007.1% of flowShareEuronext BrusselsFSMA:ucb-189
Ideal exit: 14 Jul 2026 (T+270)
60 shares@ €255.006.2% of flowShareEuronext BrusselsFSMA:ucb-11
Ideal exit: 12 Jul 2026 (T+270)
60 shares@ €245.005.9% of flowShareEuronext BrusselsFSMA:ucb-88
Ideal exit: 28 Jun 2026 (T+270)
50 shares@ €235.004.8% of flowShareEuronext BrusselsFSMA:ucb
Ideal exit: 27 Jun 2026 (T+270)
13 of 13 declarations
About Castella Maelys
Maelys Castella is a member of the administrative management at UCB, a global biopharmaceutical company. In her role, she participates in strategic decision-making and oversight of operations, contributing to the company's mission to improve patients' lives. Her expertise in the pharmaceutical sector is a valuable asset for UCB as she strives to meet industry challenges and innovate in the development of new treatments.
